AbbVie

YTD

ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.

CEO

Robert A. Michael

CEORobert A. Michael

Employees

55,000

Employees55,000

Headquarters

North Chicago, Illinois

HeadquartersNorth Chicago, Illinois

Founded

2011

Founded2011

Employees

55,000

Employees55,000

ABBV Key Statistics

Market cap

313.20B

Market cap313.20B

Price-Earnings ratio

72.70

Price-Earnings ratio72.70

Dividend yield

3.62%

Dividend yield3.62%

Average volume

10.18M

Average volume10.18M

High today

$178.15

High today$178.15

Low today

$174.40

Low today$174.40

Open price

$174.95

Open price$174.95

Volume

7.12M

Volume7.12M

52 Week high

$218.66

52 Week high$218.66

52 Week low

$153.58

52 Week low$153.58

ABBV News

Benzinga 10h

Salesforce, AbbVie, Intuitive Surgical And An Industrial Stock On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Joshua Brown, CEO and co-founder, Ritholtz Wealth Management, said he is staying long on 3M Company MMM. Supporting h...

Benzinga 1d

AbbVie's Pipeline May Be A 2026 Story, But Analyst Likes The Setup Now

Cantor Fitzgerald initiated coverage on AbbVie Inc ABBV, citing the company’s compelling mix of growth and defense with a differentiated topline profile, good v...

TipRanks 2d

AbbVie price target lowered to $200 from $223 at BofA

BofA lowered the firm’s price target on AbbVie (ABBV) to $200 from $223 and keeps a Neutral rating on the shares. The firm updated estimates for 2025 and beyond...

Analyst ratings

62%

of 29 ratings

Buy

62.1%

Hold

34.5%

Sell

3.4%